T2 Biosystems (TTOO) Stock
Company Profile
Price: $1.82
Market Cap: $31.81M
Exchange: NASDAQ
CEO: Mr. John J. Sperzel III, B.Sc.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Headquarters: Lexington, MA
Website: T2 Biosystems
Business Summary
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
T2 Biosystems Chart
T2 Biosystems News
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.
-
globenewswire.com
2024-09-20
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.
-
globenewswire.com
2024-08-27
T2 Biosystems to Attend Upcoming Investor Conferences
LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:
-
globenewswire.com
2024-08-01
T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript
T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Operator Greetings, and welcome to T2 Biosystems, Inc. Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
-
seekingalpha.com
2024-07-29
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.
-
globenewswire.com
2024-07-29
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.
-
globenewswire.com
2024-07-22
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements
LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2024 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.
-
globenewswire.com
2024-05-22
T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LEXINGTON, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants have an exercise price of $3.70 per share and are exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance.
-
globenewswire.com
2024-05-17
T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
LEXINGTON, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,025,317 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $3.70 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 17, 2024, subject to the satisfaction of customary closing conditions.
-
globenewswire.com
2024-05-15
T2 Biosystems Earnings
This section highlight's T2 Biosystems's earnings, including earnings call transcripts, earnings surprises, and key dates.
T2 Biosystems Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2024 | 2024-07-29 | $-0.97 | $-0.66 |
| Read Transcript | Q1 | 2024 | 2024-05-06 | $-1.86 | $-2.66 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-10-12 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-07 | $-0.27 | $-8.00 |
| Read Transcript | Q1 | 2023 | 2023-05-23 | $-1.20 | $-117.00 |
| Read Transcript | Q4 | 2022 | 2023-03-13 | $-1.70 | $-1.41 |
| Read Transcript | Q3 | 2022 | 2022-11-10 | $-2.04 | $-295.00 |
| Read Transcript | Q2 | 2022 | 2022-08-15 | $-4.50 | $-500.00 |
| Read Transcript | Q1 | 2022 | 2022-05-05 | $-3.50 | $-500.00 |
T2 Biosystems Earnings Dates
When is the next earnings date for TTOO?
Date: 2024-11-12Status: Unconfirmed
Time of Day: Before Market
Estimated EPS: $-0.64
When was the last earnings date for TTOO?
Date: 2024-07-29Fiscal Date Ending: 2024-06-30
EPS: $-0.66
Estimated EPS: $-0.97
Revenue: $1.95M
Estimated Revenue: $2.10M
Upcoming TTOO Earnings
| Date | Estimated EPS | Time of Day | Status |
|---|---|---|---|
| 2024-11-12 | $-0.64 | Before Market | Unconfirmed |
| 2025-02-13 | N/A | After Market | Unconfirmed |
| 2025-05-05 | N/A | After Market | Unconfirmed |
| 2025-07-28 | N/A | After Market | Unconfirmed |
Financial Statements
This section provides financial statements for T2 Biosystemsincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Revenue | $8.34M | $18.13M | $28.06M | $22.30M | $7.19M |
| Cost of Revenue | $16.76M | $21.28M | $20.70M | $21.14M | $16.02M |
| Gross Profit | $-8.43M | $-3.15M | $7.36M | $1.17M | $-8.83M |
| Gross Profit Ratio | -101.12% | -17.37% | 26.21% | 5.23% | -122.74% |
| Research and Development Expenses | $16.33M | $16.92M | $21.80M | $25.93M | $13.49M |
| General and Administrative Expenses | $- | $- | $- | $30.64M | $- |
| Selling and Marketing Expenses | $- | $- | $- | $100.00K | $- |
| Selling General and Administrative Expenses | $27.30M | $21.29M | $28.53M | $30.74M | $24.83M |
| Other Expenses | $400.00K | $62.00K | $206.00K | $31.00K | $-495.00K |
| Operating Expenses | $43.63M | $38.21M | $50.33M | $56.68M | $38.32M |
| Cost and Expenses | $60.39M | $59.49M | $71.03M | $77.81M | $54.35M |
| Interest Income | $1.00K | $14.00K | $112.00K | $8.00K | $- |
| Interest Expense | $7.35M | $5.50M | $6.59M | $6.08M | $5.34M |
| Depreciation and Amortization | $3.64M | $3.16M | $2.54M | $2.27M | $859.00K |
| EBITDA | $-51.66M | $-41.29M | $-42.66M | $-55.47M | $-46.29M |
| EBITDA Ratio | -619.77% | -227.77% | -152.02% | -248.69% | -643.60% |
| Operating Income | $-52.06M | $-41.36M | $-42.97M | $-55.51M | $-47.15M |
| Operating Income Ratio | -624.57% | -228.11% | -153.16% | -248.87% | -655.54% |
| Total Other Income Expenses Net | $-6.95M | $-5.44M | $-6.27M | $-6.81M | $-2.92M |
| Income Before Tax | $-59.01M | $-46.80M | $-49.24M | $-62.32M | $-50.08M |
| Income Before Tax Ratio | -707.93% | -258.12% | -175.50% | -279.39% | -696.19% |
| Income Tax Expense | $4.11M | $2.41M | $4.25M | $1.05M | $691.11K |
| Net Income | $-63.11M | $-49.21M | $-53.49M | $-63.37M | $-50.08M |
| Net Income Ratio | -757.19% | -271.42% | -190.66% | -284.11% | -696.19% |
| EPS | $-6934.20 | $-2027.86 | $-1683.72 | $-1242.48 | $-19.19 |
| EPS Diluted | $-6934.20 | $-2027.86 | $-1683.72 | $-1242.48 | $-19.19 |
| Weighted Average Shares Outstanding | 9.10K | 24.27K | 31.77K | 51.00K | 2.61M |
| Weighted Average Shares Outstanding Diluted | 9.10K | 24.27K | 31.77K | 51.00K | 2.61M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.68M | $3.07M | $2.54M | $2.55M | $5.25M | $7.79M | $6.96M | $6.69M | $7.43M | $6.98M | $7.23M | $5.91M | $3.68M | $5.48M | $2.08M | $1.96M | $1.47M | $1.68M | $2.06M | $1.95M |
| Cost of Revenue | $3.94M | $3.61M | $4.67M | $2.30M | $6.83M | $7.48M | $5.79M | $4.83M | $4.72M | $5.36M | $6.21M | $5.08M | $6.08M | $3.77M | $4.00M | $4.87M | $3.92M | $2.65M | $4.20M | $2.69M |
| Gross Profit | $-2.27M | $-541.00K | $-2.13M | $252.00K | $-1.59M | $312.00K | $1.17M | $1.86M | $2.71M | $1.62M | $1.03M | $830.00K | $-2.41M | $1.72M | $-1.92M | $-2.90M | $-2.45M | $-969.00K | $-2.14M | $-741.00K |
| Gross Profit Ratio | -135.18% | -17.63% | -83.54% | 9.87% | -30.28% | 4.01% | 16.76% | 27.83% | 36.46% | 23.18% | 14.22% | 14.04% | -65.49% | 31.28% | -92.25% | -147.91% | -166.64% | -57.71% | -103.88% | -37.96% |
| Research and Development Expenses | $4.10M | $4.28M | $4.94M | $3.98M | $3.96M | $4.04M | $4.67M | $5.40M | $6.38M | $5.35M | $6.66M | $8.03M | $6.38M | $4.88M | $4.47M | $3.85M | $2.66M | $3.10M | $3.72M | $3.36M |
| General and Administrative Expenses | $5.98M | $7.55M | $6.50M | $5.11M | $- | $9.71M | $- | $- | $- | $- | $- | $- | $- | $6.57M | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $-5.11M | $- | $- | $- | $- | $- | $- | $- | $100.00K | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.98M | $7.55M | $6.50M | $5.11M | $5.08M | $4.60M | $6.20M | $7.24M | $8.54M | $6.54M | $9.23M | $7.82M | $7.02M | $6.67M | $7.30M | $6.30M | $5.98M | $5.25M | $6.74M | $5.47M |
| Other Expenses | $51.00K | $17.00K | $29.00K | $- | $27.00K | $9.00K | $49.00K | $- | $- | $-5.00K | $-2.00K | $4.00K | $-77.00K | $96.00K | $-684.00K | $29.00K | $2.51M | $109.00K | $325.00K | $- |
| Operating Expenses | $10.08M | $11.83M | $11.44M | $9.09M | $9.05M | $8.63M | $10.87M | $12.64M | $14.92M | $11.90M | $15.89M | $15.85M | $13.39M | $11.55M | $11.77M | $10.15M | $11.15M | $8.35M | $10.46M | $8.83M |
| Cost and Expenses | $14.02M | $15.44M | $16.11M | $11.39M | $15.88M | $16.11M | $16.66M | $17.47M | $19.64M | $17.26M | $22.09M | $20.93M | $19.48M | $15.32M | $15.77M | $15.02M | $15.08M | $11.00M | $14.66M | $11.53M |
| Interest Income | $- | $- | $- | $1.00K | $1.00K | $- | $6.00K | $6.00K | $6.00K | $94.00K | $3.00K | $2.00K | $1.00K | $2.00K | $2.00K | $2.00K | $- | $-4.00K | $- | $- |
| Interest Expense | $1.88M | $1.69M | $1.42M | $1.84M | $646.00K | $1.60M | $1.01M | $1.70M | $1.92M | $1.95M | $1.65M | $1.35M | $1.56M | $1.53M | $1.52M | $1.54M | $-1.12M | $1.16M | $-1.18M | $-478.00K |
| Depreciation and Amortization | $1.59M | $883.00K | $897.00K | $810.00K | $765.00K | $684.00K | $811.00K | $587.00K | $584.00K | $556.00K | $580.00K | $549.00K | $570.00K | $572.00K | $577.00K | $599.00K | $262.00K | $74.00K | $64.00K | $64.00K |
| EBITDA | $-11.40M | $-12.35M | $-13.53M | $-8.83M | $-10.61M | $-8.31M | $-9.65M | $-10.19M | $-11.62M | $-10.19M | $-14.27M | $-14.47M | $-15.23M | $-9.74M | $-14.11M | $-12.75M | $-13.61M | $-9.24M | $-12.60M | $-9.57M |
| EBITDA Ratio | -680.08% | -402.44% | -531.71% | -346.04% | -202.27% | -106.72% | -138.69% | -152.18% | -156.46% | -145.99% | -197.32% | -244.76% | -414.17% | -177.57% | -679.16% | -649.34% | -924.39% | -550.63% | -611.35% | -490.52% |
| Operating Income | $-12.35M | $-12.37M | $-13.56M | $-8.84M | $-10.64M | $-8.32M | $-9.70M | $-10.78M | $-12.21M | $-10.28M | $-14.86M | $-15.02M | $-15.80M | $-9.83M | $-13.69M | $-13.05M | $-13.61M | $-9.32M | $-12.60M | $-9.57M |
| Operating Income Ratio | -736.20% | -403.00% | -532.85% | -346.36% | -202.78% | -106.83% | -139.48% | -161.04% | -164.40% | -147.26% | -205.38% | -254.09% | -429.70% | -179.35% | -658.66% | -664.51% | -924.39% | -555.03% | -611.35% | -490.52% |
| Total Other Income Expenses Net | $51.00K | $17.00K | $29.00K | $-3.00K | $27.00K | $9.00K | $49.00K | $-1.00K | $163.00K | $-5.00K | $-1.64M | $-3.02M | $-1.57M | $-579.00K | $-4.28M | $8.24M | $-1.82M | $-1.02M | $-934.00K | $332.00K |
| Income Before Tax | $-14.17M | $-14.04M | $-14.95M | $-10.69M | $-11.26M | $-9.91M | $-10.66M | $-12.47M | $-13.96M | $-12.14M | $-16.50M | $-18.03M | $-17.38M | $-10.41M | $-17.96M | $-6.35M | $-15.43M | $-10.34M | $-13.53M | $-9.24M |
| Income Before Tax Ratio | -845.02% | -457.51% | -587.39% | -418.69% | -214.59% | -127.23% | -153.25% | -186.36% | -187.96% | -173.98% | -228.02% | -305.09% | -472.53% | -189.91% | -864.53% | -323.17% | -1047.89% | -615.84% | -656.67% | -473.51% |
| Income Tax Expense | $1.93M | $824.00K | $549.00K | $1.84M | $-894.00K | $923.00K | $251.00K | $1.70M | $1.92M | $1.95M | $1.64M | $3.02M | $1.57M | $1.04M | $2.07M | $1.57M | $-262.00K | $-3.38M | $-64.00K | $-64.00K |
| Net Income | $-14.17M | $-14.04M | $-14.95M | $-10.69M | $-11.26M | $-9.91M | $-10.66M | $-12.47M | $-13.96M | $-12.14M | $-18.13M | $-21.05M | $-18.95M | $-11.45M | $-20.04M | $-6.35M | $-15.43M | $-10.34M | $-13.53M | $-9.24M |
| Net Income Ratio | -845.02% | -457.51% | -587.39% | -418.69% | -214.59% | -127.23% | -153.25% | -186.36% | -187.96% | -173.98% | -250.66% | -356.10% | -515.37% | -208.85% | -964.34% | -323.17% | -1047.89% | -615.84% | -656.67% | -473.51% |
| EPS | $-31.20 | $-14.66 | $-1089.02 | $-444.12 | $-380.76 | $-334.72 | $-359.58 | $-402.72 | $-421.01 | $-365.41 | $-533.78 | $-595.33 | $-315.75 | $-154.62 | $-146.98 | $-7.84 | $-3.45 | $-2.08 | $-2.66 | $-0.66 |
| EPS Diluted | $-31.20 | $-14.66 | $-1089.02 | $-444.12 | $-380.76 | $-334.72 | $-359.58 | $-402.72 | $-420.85 | $-365.40 | $-533.78 | $-595.33 | $-315.37 | $-154.62 | $-146.98 | $-7.84 | $-3.45 | $-2.08 | $-2.66 | $-0.66 |
| Weighted Average Shares Outstanding | 454.13K | 957.93K | 13.73K | 24.06K | 29.56K | 29.60K | 29.65K | 30.98K | 33.16K | 33.23K | 33.97K | 35.36K | 60.02K | 74.06K | 136.33K | 809.17K | 4.48M | 4.97M | 5.09M | 14.10M |
| Weighted Average Shares Outstanding Diluted | 454.13K | 957.93K | 13.73K | 24.06K | 29.56K | 29.60K | 29.65K | 30.98K | 33.18K | 33.23K | 33.97K | 35.36K | 60.09K | 74.06K | 136.33K | 809.17K | 4.48M | 4.97M | 5.09M | 14.10M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $11.03M | $16.79M | $22.25M | $10.33M | $15.69M |
| Short Term Investments | $- | $25.40M | $10.00M | $- | $- |
| Cash and Short Term Investments | $11.03M | $42.19M | $32.24M | $10.33M | $15.69M |
| Net Receivables | $2.83M | $5.10M | $5.13M | $2.16M | $1.42M |
| Inventory | $3.60M | $3.64M | $3.91M | $4.35M | $4.82M |
| Other Current Assets | $1.44M | $2.66M | $3.11M | $2.58M | $3.16M |
| Total Current Assets | $18.89M | $53.58M | $44.39M | $19.42M | $25.09M |
| Property Plant Equipment Net | $9.21M | $14.80M | $14.44M | $13.27M | $9.05M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $10.00M | $1.55M | $1.65M | $651.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $386.00K | $687.00K | $153.00K | $43.00K | $4.00K |
| Total Non-Current Assets | $9.59M | $25.49M | $16.14M | $14.97M | $9.71M |
| Other Assets | $- | $- | $- | $- | $-0.00B |
| Total Assets | $28.49M | $79.08M | $60.54M | $34.39M | $34.80M |
| Account Payables | $3.75M | $2.06M | $2.83M | $1.30M | $1.53M |
| Short Term Debt | $42.90M | $1.15M | $1.17M | $1.35M | $42.90M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $285.00K | $230.00K | $518.00K | $172.00K | $224.00K |
| Other Current Liabilities | $13.63M | $6.36M | $7.16M | $7.69M | $11.50M |
| Total Current Liabilities | $60.57M | $9.80M | $11.69M | $10.51M | $56.15M |
| Long Term Debt | $1.87M | $55.77M | $57.15M | $57.87M | $6.60M |
| Deferred Revenue Non-Current | $46.00K | $424.00K | $28.00K | $52.00K | $83.00K |
| Deferred Tax Liabilities Non-Current | $-46.00K | $1.01M | $- | $- | $- |
| Other Non-Current Liabilities | $46.00K | $3.35M | $4.58M | $5.94M | $--0.00B |
| Total Non-Current Liabilities | $1.92M | $60.55M | $61.75M | $63.85M | $6.68M |
| Other Liabilities | $- | $- | $- | $- | $-0.00B |
| Total Liabilities | $62.49M | $70.35M | $73.44M | $74.36M | $62.83M |
| Preferred Stock | $-0.00B | $- | $- | $- | $-0.00B |
| Common Stock | $49.00K | $147.00K | $166.00K | $8.00K | $4.00K |
| Retained Earnings | $-376.18M | $-422.98M | $-472.22M | $-534.53M | $-584.30M |
| Accumulated Other Comprehensive Income Loss | $-0.00B | $9.00K | $-4.00K | $- | $-0.00B |
| Other Total Stockholders Equity | $342.12M | $431.55M | $459.15M | $494.56M | $556.26M |
| Total Stockholders Equity | $-34.01M | $8.73M | $-12.90M | $-39.97M | $-28.04M |
| Total Equity | $-34.01M | $8.73M | $-12.90M | $-39.97M | $-28.04M |
| Total Liabilities and Stockholders Equity | $28.49M | $79.08M | $60.54M | $34.39M | $34.80M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $28.49M | $79.08M | $60.54M | $34.39M | $34.80M |
| Total Investments | $- | $35.40M | $10.00M | $1.65M | $651.00K |
| Total Debt | $44.77M | $55.77M | $57.15M | $59.22M | $49.50M |
| Net Debt | $33.74M | $38.98M | $34.90M | $48.89M | $33.81M |
Quarterly Balance Sheet
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $16.21M | $11.03M | $36.32M | $26.55M | $19.06M | $16.79M | $10.69M | $32.71M | $22.05M | $22.25M | $9.40M | $13.21M | $20.37M | $10.33M | $10.12M | $16.08M | $24.32M | $15.69M | $6.21M | $4.25M |
| Short Term Investments | $- | $- | $- | $9.25M | $21.99M | $25.40M | $22.62M | $20.08M | $20.04M | $10.00M | $9.99M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $16.21M | $11.03M | $36.32M | $35.80M | $41.05M | $42.19M | $33.31M | $52.79M | $42.09M | $32.24M | $19.39M | $13.21M | $20.37M | $10.33M | $10.12M | $16.08M | $24.32M | $15.69M | $6.21M | $4.25M |
| Net Receivables | $1.57M | $2.83M | $2.45M | $1.30M | $3.86M | $5.10M | $4.03M | $3.98M | $4.22M | $5.13M | $4.36M | $2.72M | $1.58M | $2.16M | $1.32M | $1.35M | $1.14M | $1.42M | $1.59M | $1.30M |
| Inventory | $4.11M | $3.60M | $3.27M | $4.11M | $3.57M | $3.64M | $4.53M | $4.78M | $4.82M | $3.91M | $5.17M | $5.67M | $4.24M | $4.35M | $4.94M | $4.34M | $4.28M | $4.82M | $4.67M | $5.17M |
| Other Current Assets | $1.92M | $1.44M | $1.72M | $6.17M | $2.97M | $2.66M | $2.72M | $2.31M | $3.33M | $3.11M | $4.58M | $3.10M | $2.69M | $2.58M | $2.55M | $2.10M | $3.14M | $3.16M | $3.09M | $2.28M |
| Total Current Assets | $23.81M | $18.89M | $43.77M | $47.37M | $51.45M | $53.58M | $44.59M | $63.86M | $54.46M | $44.39M | $33.50M | $24.70M | $28.88M | $19.42M | $18.93M | $23.87M | $32.88M | $25.09M | $15.56M | $13.00M |
| Property Plant Equipment Net | $10.05M | $9.21M | $7.20M | $5.98M | $5.31M | $14.80M | $14.81M | $14.41M | $13.87M | $14.44M | $14.25M | $13.62M | $13.79M | $13.27M | $13.22M | $12.66M | $9.79M | $9.05M | $8.64M | $8.17M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $20.19M | $10.00M | $10.00M | $551.00K | $1.55M | $1.55M | $1.13M | $1.13M | $1.13M | $1.65M | $751.00K | $551.00K | $551.00K | $651.00K | $651.00K | $651.00K |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $386.00K | $386.00K | $386.00K | $366.00K | $684.00K | $687.00K | $655.00K | $78.00K | $161.00K | $153.00K | $155.00K | $156.00K | $153.00K | $43.00K | $-165.00K | $49.00K | $65.00K | $4.00K | $-98.00K | $-99.00K |
| Total Non-Current Assets | $10.44M | $9.59M | $7.58M | $6.34M | $26.18M | $25.49M | $25.46M | $15.04M | $15.58M | $16.14M | $15.54M | $14.90M | $15.08M | $14.97M | $13.81M | $13.26M | $10.40M | $9.71M | $9.19M | $8.72M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B | $-0.00B | $- |
| Total Assets | $34.25M | $28.49M | $51.35M | $53.71M | $77.63M | $79.08M | $70.05M | $78.90M | $70.04M | $60.54M | $49.04M | $39.60M | $43.95M | $34.39M | $32.73M | $37.13M | $43.28M | $34.80M | $24.75M | $21.72M |
| Account Payables | $3.43M | $3.75M | $1.69M | $1.78M | $2.41M | $2.06M | $3.91M | $2.89M | $2.62M | $2.83M | $3.38M | $5.23M | $2.06M | $1.30M | $3.13M | $2.23M | $1.09M | $1.53M | $1.89M | $1.69M |
| Short Term Debt | $44.17M | $42.90M | $43.40M | $2.01M | $1.94M | $1.15M | $1.17M | $1.17M | $1.17M | $1.17M | $1.20M | $1.22M | $1.29M | $1.35M | $1.42M | $52.05M | $42.45M | $42.90M | $43.32M | $13.47M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $610.00K | $285.00K | $238.00K | $199.00K | $290.00K | $230.00K | $400.00K | $438.00K | $613.00K | $518.00K | $338.00K | $142.00K | $163.00K | $172.00K | $149.00K | $265.00K | $276.00K | $224.00K | $185.00K | $237.00K |
| Other Current Liabilities | $9.49M | $13.63M | $12.34M | $3.96M | $5.71M | $6.36M | $4.93M | $4.85M | $7.00M | $7.16M | $7.75M | $6.60M | $7.42M | $7.69M | $13.13M | $11.51M | $11.64M | $11.50M | $10.87M | $6.40M |
| Total Current Liabilities | $57.70M | $60.57M | $57.67M | $7.95M | $10.35M | $9.80M | $10.40M | $9.35M | $11.40M | $11.69M | $12.67M | $13.19M | $10.94M | $10.51M | $17.83M | $66.06M | $55.45M | $56.15M | $56.26M | $21.80M |
| Long Term Debt | $2.39M | $1.87M | $1.35M | $44.92M | $45.09M | $55.77M | $56.11M | $56.45M | $56.80M | $57.15M | $57.32M | $57.46M | $57.76M | $57.87M | $57.94M | $7.43M | $7.02M | $6.60M | $6.18M | $5.75M |
| Deferred Revenue Non-Current | $77.00K | $46.00K | $32.00K | $17.00K | $300.00K | $424.00K | $281.00K | $146.00K | $50.00K | $28.00K | $47.00K | $88.00K | $8.00K | $52.00K | $74.00K | $64.00K | $40.00K | $83.00K | $92.00K | $74.00K |
| Deferred Tax Liabilities Non-Current | $-2.39M | $-1.87M | $-1.35M | $2.39M | $1.24M | $1.01M | $181.00K | $- | $- | $- | $- | $- | $- | $- | $- | $-64.00K | $-40.00K | $-6.60M | $-92.00K | $-74.00K |
| Other Non-Current Liabilities | $2.39M | $1.87M | $1.35M | $2.82M | $3.08M | $3.35M | $3.65M | $3.95M | $4.25M | $4.58M | $4.65M | $6.38M | $6.91M | $5.94M | $6.78M | $64.00K | $40.00K | $6.60M | $92.00K | $74.00K |
| Total Non-Current Liabilities | $2.47M | $1.92M | $1.38M | $50.15M | $49.71M | $60.55M | $60.22M | $60.54M | $61.10M | $61.75M | $62.02M | $63.93M | $64.68M | $63.85M | $64.79M | $7.50M | $7.06M | $6.68M | $6.27M | $5.82M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0.00B | $-0.00B | $- |
| Total Liabilities | $60.16M | $62.49M | $59.05M | $58.10M | $60.06M | $70.35M | $70.62M | $69.89M | $72.50M | $73.44M | $74.69M | $77.12M | $75.62M | $74.36M | $82.62M | $73.55M | $62.52M | $62.83M | $62.53M | $27.62M |
| Preferred Stock | $- | $2.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $330.00K | $- | $- | $- | $- | $-0.00B | $- | $- |
| Common Stock | $45.00K | $49.00K | $119.00K | $128.00K | $147.00K | $147.00K | $148.00K | $165.00K | $166.00K | $166.00K | $171.00K | $198.00K | $7.00K | $8.00K | $21.00K | $242.00K | $4.00K | $4.00K | $6.00K | $17.00K |
| Retained Earnings | $-362.14M | $-376.18M | $-391.13M | $-401.81M | $-413.07M | $-422.98M | $-433.63M | $-446.11M | $-460.07M | $-472.22M | $-488.71M | $-506.75M | $-524.12M | $-534.53M | $-552.18M | $-558.53M | $-573.96M | $-584.30M | $-597.83M | $-606.79M |
| Accumulated Other Comprehensive Income Loss | $-12.80M | $-13.24M | $-13.69M | $-14.03M | $-36.00K | $9.00K | $16.00K | $4.00K | $4.00K | $-4.00K | $-11.00K | $- | $- | $- | $- | $- | $- | $-0.00B | $- | $- |
| Other Total Stockholders Equity | $348.98M | $355.36M | $397.00M | $411.32M | $430.53M | $431.55M | $432.90M | $454.95M | $457.44M | $459.15M | $462.90M | $469.03M | $492.11M | $494.56M | $502.28M | $521.87M | $554.72M | $556.26M | $560.05M | $600.88M |
| Total Stockholders Equity | $-25.91M | $-34.01M | $-7.70M | $-4.39M | $17.57M | $8.73M | $-566.00K | $9.01M | $-2.46M | $-12.90M | $-25.65M | $-37.52M | $-31.67M | $-39.97M | $-49.89M | $-36.42M | $-19.24M | $-28.04M | $-37.77M | $-5.90M |
| Total Equity | $-25.91M | $-34.01M | $-7.70M | $-4.39M | $17.57M | $8.73M | $-566.00K | $9.01M | $-2.46M | $-12.90M | $-25.65M | $-37.52M | $-31.67M | $-39.97M | $-49.89M | $-36.42M | $-19.24M | $-28.04M | $-37.77M | $-5.90M |
| Total Liabilities and Stockholders Equity | $34.25M | $28.49M | $51.35M | $53.71M | $77.63M | $79.08M | $70.05M | $78.90M | $70.04M | $60.54M | $49.04M | $39.60M | $43.95M | $34.39M | $32.73M | $37.13M | $43.28M | $34.80M | $24.75M | $21.72M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $34.25M | $28.49M | $51.35M | $53.71M | $77.63M | $79.08M | $70.05M | $78.90M | $70.04M | $60.54M | $49.04M | $39.60M | $43.95M | $34.39M | $32.73M | $37.13M | $43.28M | $34.80M | $24.75M | $21.72M |
| Total Investments | $- | $- | $- | $9.25M | $42.18M | $35.40M | $32.62M | $20.08M | $20.04M | $10.00M | $9.99M | $1.13M | $1.13M | $1.65M | $751.00K | $551.00K | $551.00K | $651.00K | $651.00K | $651.00K |
| Total Debt | $46.56M | $44.77M | $44.75M | $46.93M | $45.09M | $55.77M | $56.11M | $57.62M | $57.97M | $57.15M | $58.51M | $58.68M | $59.05M | $59.22M | $59.35M | $59.48M | $49.48M | $49.50M | $49.50M | $19.22M |
| Net Debt | $30.35M | $33.74M | $8.43M | $20.39M | $26.03M | $38.98M | $45.42M | $24.91M | $35.92M | $34.90M | $49.12M | $45.47M | $38.69M | $48.89M | $49.24M | $43.40M | $25.16M | $33.81M | $43.29M | $14.97M |
Annual Cash Flow Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Net Income | $-59.01M | $-46.80M | $-49.24M | $-62.00M | $-50.08M |
| Depreciation and Amortization | $3.64M | $3.16M | $2.54M | $2.27M | $859.00K |
| Deferred Income Tax | $280.00K | $-258.00K | $-1.02M | $- | $-230.00K |
| Stock Based Compensation | $5.46M | $3.91M | $7.09M | $6.49M | $4.35M |
| Change in Working Capital | $1.86M | $-6.54M | $-2.17M | $-503.00K | $-4.04M |
| Accounts Receivables | $-1.04M | $-2.27M | $-35.00K | $2.97M | $743.00K |
| Inventory | $-914.00K | $441.00K | $-1.94M | $-949.00K | $-744.00K |
| Accounts Payables | $2.96M | $-1.65M | $761.00K | $-1.57M | $231.00K |
| Other Working Capital | $851.00K | $-3.05M | $-957.00K | $-959.00K | $-4.27M |
| Other Non Cash Items | $2.41M | $3.31M | $3.93M | $3.11M | $941.00K |
| Net Cash Provided by Operating Activities | $-45.36M | $-43.22M | $-38.87M | $-50.63M | $-48.20M |
| Investments in Property Plant and Equipment | $-761.00K | $-804.00K | $-460.00K | $-339.00K | $-192.00K |
| Acquisitions Net | $- | $4.00K | $- | $- | $- |
| Purchases of Investments | $- | $-50.71M | $- | $- | $- |
| Sales Maturities of Investments | $- | $15.25M | $25.25M | $10.00M | $- |
| Other Investing Activities | $- | $-35.46M | $25.25M | $10.00M | $- |
| Net Cash Used for Investing Activities | $-761.00K | $-36.26M | $24.79M | $9.66M | $-192.00K |
| Debt Repayment | $-882.00K | $- | $- | $- | $- |
| Common Stock Issued | $6.65M | $85.31M | $20.54M | $29.16M | $52.75M |
| Common Stock Repurchased | $- | $- | $- | $-330.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $582.00K | $296.00K | $20.54M | $222.00K | $52.69M |
| Net Cash Used Provided by Financing Activities | $6.35M | $85.61M | $20.54M | $29.05M | $52.69M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $1.00M |
| Net Change in Cash | $-39.77M | $6.13M | $6.45M | $-11.92M | $5.36M |
| Cash at End of Period | $11.21M | $17.34M | $23.80M | $11.88M | $15.69M |
| Cash at Beginning of Period | $50.98M | $11.21M | $17.34M | $23.80M | $10.33M |
| Operating Cash Flow | $-45.36M | $-43.22M | $-38.87M | $-50.63M | $-48.20M |
| Capital Expenditure | $-761.00K | $-804.00K | $-460.00K | $-339.00K | $-192.00K |
| Free Cash Flow | $-46.12M | $-44.02M | $-39.33M | $-50.97M | $-48.39M |
Quarterly Cash Flow Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-14.17M | $-14.04M | $-14.95M | $-10.69M | $-11.26M | $-9.91M | $-10.66M | $-12.47M | $-13.96M | $-12.14M | $-16.50M | $-18.03M | $-17.38M | $-10.10M | $-17.96M | $-6.35M | $-15.43M | $-10.34M | $-13.53M | $-8.96M |
| Depreciation and Amortization | $890.00K | $883.00K | $897.00K | $8.00K | $1.57M | $684.00K | $811.00K | $587.00K | $584.00K | $556.00K | $580.00K | $549.00K | $570.00K | $572.00K | $256.00K | $267.00K | $262.00K | $74.00K | $64.00K | $62.00K |
| Deferred Income Tax | $100.00K | $-178.00K | $518.00K | $605.00K | $-1.16M | $-225.00K | $-831.00K | $-193.00K | $- | $- | $- | $- | $- | $- | $- | $-8.21M | $3.26M | $-923.00K | $- | $- |
| Stock Based Compensation | $1.17M | $983.00K | $1.16M | $994.00K | $855.00K | $904.00K | $1.31M | $1.84M | $2.47M | $1.47M | $2.55M | $1.53M | $1.37M | $1.03M | $1.83M | $913.00K | $877.00K | $728.00K | $1.59M | $208.00K |
| Change in Working Capital | $-2.13M | $1.59M | $-2.99M | $-6.07M | $3.69M | $-1.17M | $-289.00K | $-1.33M | $193.00K | $-744.00K | $-1.62M | $3.81M | $-1.06M | $-1.63M | $-670.00K | $138.00K | $-2.99M | $-523.00K | $-593.00K | $93.00K |
| Accounts Receivables | $-394.00K | $-1.25M | $371.00K | $1.15M | $-2.56M | $-1.24M | $1.06M | $55.00K | $-243.00K | $-912.00K | $773.00K | $1.64M | $1.14M | $-585.00K | $840.00K | $-26.00K | $210.00K | $-281.00K | $-168.00K | $291.00K |
| Inventory | $-582.00K | $550.00K | $845.00K | $-826.00K | $704.00K | $-282.00K | $-1.43M | $-387.00K | $-102.00K | $-25.00K | $-1.53M | $-348.00K | $1.07M | $-134.00K | $-949.00K | $575.00K | $-165.00K | $-205.00K | $149.00K | $-499.00K |
| Accounts Payables | $666.00K | $277.00K | $-2.02M | $38.00K | $702.00K | $-371.00K | $1.80M | $-975.00K | $-300.00K | $238.00K | $553.00K | $1.84M | $-3.18M | $-775.00K | $1.83M | $-895.00K | $-1.15M | $439.00K | $358.00K | $-199.00K |
| Other Working Capital | $-1.82M | $2.02M | $-2.18M | $-6.43M | $4.84M | $723.00K | $-1.73M | $-24.00K | $838.00K | $-45.00K | $-1.41M | $676.00K | $-89.00K | $-133.00K | $-2.39M | $484.00K | $-1.89M | $-476.00K | $-932.00K | $500.00K |
| Other Non Cash Items | $609.00K | $644.00K | $621.00K | $1.66M | $69.00K | $965.00K | $953.00K | $972.00K | $992.00K | $1.02M | $543.00K | $2.19M | $592.00K | $-210.00K | $3.61M | $856.00K | $623.00K | $1.57M | $2.17M | $98.00K |
| Net Cash Provided by Operating Activities | $-13.54M | $-10.12M | $-14.74M | $-13.49M | $-6.23M | $-8.75M | $-8.71M | $-10.60M | $-9.73M | $-9.84M | $-14.44M | $-9.96M | $-15.90M | $-10.33M | $-12.94M | $-12.39M | $-13.39M | $-9.42M | $-11.68M | $-9.24M |
| Investments in Property Plant and Equipment | $-291.00K | $-26.00K | $-67.00K | $-60.00K | $-298.00K | $-379.00K | $-197.00K | $-106.00K | $42.00K | $-199.00K | $-29.00K | $-148.00K | $-126.00K | $-36.00K | $-120.00K | $-33.00K | $-13.00K | $-26.00K | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $-15.45M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $-41.22M | $-249.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $8.25M | $7.00M | $2.75M | $12.50M | $- | $10.00M | $- | $10.00M | $- | $10.00M | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-9.24M | $8.25M | $15.45M | $2.75M | $12.50M | $- | $10.00M | $- | $10.00M | $- | $-10.00M | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-291.00K | $-26.00K | $-67.00K | $-9.30M | $-33.26M | $6.37M | $2.55M | $12.39M | $42.00K | $9.80M | $-29.00K | $9.85M | $-126.00K | $-36.00K | $-120.00K | $-33.00K | $-13.00K | $-26.00K | $- | $- |
| Debt Repayment | $-320.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $1.94M | $4.38M | $40.10M | $12.82M | $32.39M | $- | $53.00K | $20.22M | $24.00K | $239.00K | $1.43M | $3.79M | $22.88M | $1.05M | $11.85M | $18.39M | $21.70M | $812.00K | $2.20M | $7.28M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-230.00K | $-12.00K | $-1.00K | $-330.00K | $- | $- | $1.93M | $-1.93M | $-1.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.94M | $582.00K | $40.10M | $180.00K | $4.00K | $112.00K | $53.00K | $20.22M | $24.00K | $239.00K | $-230.00K | $127.00K | $300.00K | $26.00K | $11.85M | $18.39M | $21.64M | $812.00K | $-1.00K | $- |
| Net Cash Used Provided by Financing Activities | $1.62M | $4.96M | $40.10M | $13.00M | $32.40M | $112.00K | $53.00K | $20.22M | $24.00K | $239.00K | $1.20M | $3.92M | $23.18M | $748.00K | $11.85M | $18.39M | $21.64M | $812.00K | $2.20M | $7.28M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.45M | $-6.30M | $10.75M | $- | $- |
| Net Change in Cash | $-12.21M | $-5.18M | $25.29M | $-9.79M | $-7.10M | $-2.27M | $-6.10M | $22.02M | $-9.66M | $198.00K | $-13.27M | $3.81M | $7.15M | $-9.62M | $-1.21M | $5.97M | $8.23M | $-8.63M | $-9.48M | $-1.96M |
| Cash at End of Period | $16.39M | $11.21M | $36.50M | $26.71M | $19.61M | $17.34M | $11.24M | $33.26M | $23.60M | $23.80M | $10.53M | $14.34M | $21.50M | $11.88M | $10.67M | $16.64M | $24.87M | $15.69M | $6.21M | $4.25M |
| Cash at Beginning of Period | $28.60M | $16.39M | $11.21M | $36.50M | $26.71M | $19.61M | $17.34M | $11.24M | $33.26M | $23.60M | $23.80M | $10.53M | $14.34M | $21.50M | $11.88M | $10.67M | $16.64M | $24.32M | $15.69M | $6.21M |
| Operating Cash Flow | $-13.54M | $-10.12M | $-14.74M | $-13.49M | $-6.23M | $-8.75M | $-8.71M | $-10.60M | $-9.73M | $-9.84M | $-14.44M | $-9.96M | $-15.90M | $-10.33M | $-12.94M | $-12.39M | $-13.39M | $-9.42M | $-11.68M | $-9.24M |
| Capital Expenditure | $-291.00K | $-26.00K | $-67.00K | $-60.00K | $-298.00K | $-379.00K | $-197.00K | $-106.00K | $42.00K | $-199.00K | $-29.00K | $-148.00K | $-126.00K | $-36.00K | $-120.00K | $-33.00K | $-13.00K | $-26.00K | $- | $- |
| Free Cash Flow | $-13.83M | $-10.14M | $-14.81M | $-13.55M | $-6.53M | $-9.13M | $-8.90M | $-10.70M | $-9.69M | $-10.04M | $-14.47M | $-10.10M | $-16.03M | $-10.37M | $-13.06M | $-12.42M | $-13.41M | $-9.44M | $-11.68M | $-9.24M |
T2 Biosystems Dividends
Understand T2 Biosystems's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
251.03x
T2 Biosystems Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|
Valuation
Analyze the market cap, enterprise value, and valuation metrics for T2 Biosystems.
Market Cap & Enterprise Value
Market Cap: $31.81M
Enterprise Value: $50.20M
Valuation Ratios
P/E Ratio: -0.33
P/B Ratio: -0.58
P/CF Ratio: -0.34
Valuation Multiples
E/V to Sales: 6.98
E/V to EBITDA: -1.08
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
T2 Biosystems Growth
View income_statement_chart2_annual_data financial growth metrics for T2 Biosystems, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: -5.29%
Operating Income Growth: 24.01%
Cash Flow Growth
Net Income Growth: 33.77%
Free Cash Flow Growth: 20.90%
Balance Sheet Growth
Total Assets Growth: -12.26%
Total Liabilities Growth: -55.83%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
|
$- | $ | $ | $ | $ |
Biocept, Inc.
BIOC
|
$- | $0.43 | $-56.78 | $-0.28 | $1.01 |
Genetic Technologies Limited
GENE
|
$6.94M | $0.73 | $-0.10 | $-21.22 | $139.33 |
HTG Molecular Diagnostics, Inc.
HTGM
|
$1.06M | $0.48 | $-24.28 | $-0.16 | $0.66 |
Intelligent Bio Solutions Inc.
INBS
|
$6.76M | $1.59 | $-6.39 | $-0.29 | $0.35 |
Interpace Biosciences, Inc.
IDXG
|
$8.83M | $2.01 | $0.19 | $5.81 | $-0.31 |
bioAffinity Technologies, Inc.
BIAF
|
$24.55M | $1.82 | $-0.91 | $-1.62 | $2.65 |
SeqLL Inc.
SQL
|
$185.31M | $6.60 | $0.00 | $0.00 | $0.00 |
Thermo Fisher Scientific Inc.
TMO
|
$228.67B | $598.61 | $15.53 | $34.18 | $4.39 |
Illumina, Inc.
ILMN
|
$22.53B | $141.43 | $-7.35 | $-18.42 | $3.72 |
Danaher Corporation
DHR
|
$195.02B | $270.03 | $6.47 | $35.76 | $3.19 |
Waters Corporation
WAT
|
$20.93B | $352.51 | $10.87 | $30.28 | $16.91 |
IDEXX Laboratories, Inc.
IDXX
|
$39.32B | $477.67 | $10.17 | $54.56 | $31.06 |
iSpecimen Inc.
ISPC
|
$3.42M | $5.23 | $-1.23 | $-8.15 | $9.29 |
More metrics for T2 Biosystems
Access more key metrics, financials, ratios, and more with the links below.